Summary of Key Information:

Reporting Period: Quarter and Year Ended 31st March, 2026

Nature of Filing / Announcement: Regulatory filing under SEBI Listing Regulations 30 and 33

Audit Opinion:

Unmodified opinion issued by M/s. D. Kothary & Co., Statutory Auditors

Key Financial Highlights [₹ lakhs]:

Standalone Results:

Quarter Ended March 31, 2026:

  • Revenue from Operations: ₹2,803.07
  • Other Income: ₹50.98
  • Total Income: ₹2,854.05
  • Total Expenses: ₹3,543.04
  • Loss before Exceptional Items and Taxes: ₹(688.99)
  • Exceptional Items (Impairment): ₹2,301.44
  • Loss before Tax: ₹(2,990.43)
  • Net Loss after Tax: ₹(2,977.21)
  • EPS: ₹(8.34)
  • Other Equity: Not specified for quarter

Year Ended March 31, 2026:

  • Revenue from Operations: ₹12,090.53
  • Other Income: ₹397.44
  • Total Income: ₹12,487.97
  • Total Expenses: ₹13,510.06
  • Loss before Exceptional Items and Taxes: ₹(1,022.09)
  • Exceptional Items (Impairment): ₹2,301.44
  • Loss before Tax: ₹(3,323.53)
  • Net Loss after Tax: ₹(3,228.84)
  • EPS: ₹(9.05)
  • Other Equity: ₹5,130.91
  • Cash and Cash Equivalents: ₹118.62
  • Total Debt: ₹4,835.59 (Non-current borrowings ₹2,298.93 + Current borrowings ₹2,536.66)

Consolidated Results:

Year Ended March 31, 2026:

  • Revenue from Operations: ₹13,194.24
  • Other Income: ₹355.90
  • Total Income: ₹13,550.14
  • Total Expenses: ₹14,372.18
  • Loss before Exceptional Items and Taxes: ₹(1,177.94)
  • Net Loss after Tax: ₹(1,043.56)
  • Profit After Tax Attributable to Owners: ₹(1,003.18)
  • Non-controlling Interest: ₹(40.40)
  • EPS: ₹(2.81)
  • Other Equity: ₹5,670.35
  • Cash and Cash Equivalents: ₹135.91

Segment-wise Performance:

The Company operates in one business segment only: "Pharmaceuticals"

Corporate Actions:

Dividend: Not declared

Record Date: Thursday, June 04, 2026 fixed for determining equity shareholders entitled to receive equity shares pursuant to Scheme of Amalgamation with Lyka Exports Limited

Share Allotment: 23 fully paid-up equity shares of Transferee Company (face value ₹10) to be issued for every 100 shares held in Transferor Company

Pending Share Issuance: 4,62,712 equity shares pending allotment to shareholders of erstwhile Lyka Export Limited

Other Significant Information:

Assets and Liabilities (Standalone as at March 31, 2026):

  • Total Assets: ₹17,074.66 lakhs
  • Property, Plant and Equipment: ₹8,040.07 lakhs
  • Inventories: ₹1,362.96 lakhs
  • Trade Receivables: ₹3,291.47 lakhs
  • Total Equity: ₹8,699.91 lakhs
  • Total Liabilities: ₹8,374.75 lakhs

Cash Flow (Standalone FY26):

  • Net cashflow from operating activities: ₹508.63 lakhs
  • Net cash used in investing activities: ₹(942.32) lakhs
  • Net cash from financing activities: ₹419.44 lakhs
  • Net decrease in cash: ₹(14.25) lakhs

Subsidiary Information (Consolidated):

  • Lyka BDR International Limited: Total assets ₹422.94 lakhs, total income ₹12.47 lakhs (quarter) and ₹1,055.48 lakhs (year), net loss ₹(129.22) lakhs (quarter) and ₹(116.18) lakhs (year)

Annual General Meeting:

47th Annual General Meeting to be held on Monday, 10th August, 2026 through permission mode